Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019448 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00019448: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00019448 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019448, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients with metastatic melanoma that has not responded to previous treatment.
Interventions
- DRUG gp100 antigen
- DRUG interleukin-2
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-09 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019448
The ClinicalTrials.gov registry entry for NCT00019448 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gp100 antigen is the first listed.
NCT00019448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019448 about?
NCT00019448 is a clinical study titled "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma". RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectivenes...
What is the current status of trial NCT00019448?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-09. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00019448?
The interventions under investigation include: gp100 antigen (DRUG), interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT00019448?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.